Armanni-Ebstein Lesions in Terminal Hyperglycemia

J Forensic Sci. 2017 Jul;62(4):921-925. doi: 10.1111/1556-4029.13360. Epub 2016 Dec 16.

Abstract

Armanni-Ebstein lesions (AEL) occur in deaths related to uncontrolled diabetes mellitus. To investigate the relationship between AEL and terminal hyperglycemia, we retrospectively reviewed 71 cases with vitreous glucose levels ≥11.1 mmol/L; 27 (38%) cases had AEL (vitreous glucose 14.0-77.3 mmol/L); and 44 cases (62%) did not (vitreous glucose 11.1-91.9 mmol/L). There was no significant difference (p = 0.271) in vitreous glucose levels between the cases with AEL (mean 39.2, SD 16.7 mmol/L) and those without (mean 34.2, SD 19.8 mmol/L). Similarly, there was no difference in the degree of dehydration, renal failure, or osmolality. However, there was a significantly higher level of β-hydroxybutyrate among the cases with AEL compared to those without (p = 0.007), suggesting that ketoacidosis may facilitate the development of AEL. Given the possible synergistic role of β-hydroxybutyrate, the correlation between AEL and terminal hyperglycemia in animal studies may not be applicable to humans. AEL may also possibly occur with sublethal elevations in glucose.

Keywords: Armanni-Ebstein phenomenon; diabetes mellitus; forensic science; glycogen nephrosis; hyperglycemia; renal tubular vacuolization.

MeSH terms

  • 3-Hydroxybutyric Acid / metabolism
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Epithelial Cells / pathology*
  • Female
  • Glucose / metabolism
  • Humans
  • Hyperglycemia / pathology*
  • Ketosis / pathology
  • Kidney Tubules / cytology*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Vacuoles / pathology*
  • Vitreous Body / metabolism
  • Young Adult

Substances

  • Glucose
  • 3-Hydroxybutyric Acid